Prospective Acceptability of Digital Therapy for Major Depressive Disorder in France: Multicentric Real-Life Study.

BACKGROUND: Major depressive disorder is one of the leading causes of disability worldwide. Although most international guidelines recommend psychological and psychosocial interventions as first-line treatment for mild to moderate depression, access remains limited in France due to the limited availability of trained clinicians, high costs for patients in the context of nonreimbursement, and the fear of stigmatization. Therefore, online blended psychological treatment such as Deprexis could improve access to care for people with depression. It has several advantages, such as easy accessibility and scalability, and it is supported by evidence. OBJECTIVE: This study aims to evaluate the real-life acceptability of Deprexis for people with depression in France outside of a reimbursement pathway. METHODS: Deprexis Acceptability Study Measure in Real Life (DARE) was designed as a multicenter cross-sectional study in which Deprexis was offered to any patient meeting the inclusion criteria during the fixed inclusion period (June 2022-March 2023). Inclusion criteria were (1) depression, (2) age between 18 and 65 years, (3) sufficient French language skills, and (4) access to the internet with a device to connect to the Deprexis platform. Exclusion criteria were previous or current diagnoses of bipolar disorder, psychotic symptoms, and suicidal thoughts during the current episode. The primary objective was to measure the prospective acceptability of Deprexis, a new digital therapy. Secondary objectives were to examine differences in acceptability according to patient and clinician characteristics and to identify reasons for refusal. All investigators received video-based training on Deprexis before enrollment to ensure that they all had the same level of information and understanding of the program. RESULTS: A total of 245 patients were eligible (n=159, 64.9% were women and n=138, 56.3% were single). The mean age was 40.7 (SD 14.1) years. A total of 78% (n=191) of the patients had moderate to severe depression (according to the Patient Health Questionnaire-9 [PHQ-9]). More than half of the population had another psychiatric comorbidity (excluding bipolar disorder, psychotic disorders, and suicidal ideation). A total of 33.9% (n=83) of patients accepted the idea of using Deprexis; the main reason for refusal was financial at 83.3% (n=135). Multivariate logistic regression identified factors that might favor the acceptability of Deprexis. Among these, being a couple, being treated with an antidepressant, or having a low severity level favored the acceptance of Deprexis. CONCLUSIONS: DARE is the first French study aiming at evaluating the prospective acceptability of digital therapy in the treatment of depression. The main reason for the refusal of Deprexis was financial. DARE will allow better identification of factors influencing acceptability in a natural setting. This study highlights the importance of investigating factors that may be associated with the acceptability of digital interventions, such as marital status, medication use, and severity of depression.

Understanding the potential of digital therapies in implementing the standard of care for depression in Europe.

Depressive disorders represent the largest proportion of mental illnesses, and by 2030, they are expected to be the first cause of disability-adjusted life years [1]. The COVID-19 pandemic exacerbated prevalence and burden of depression and increased the occurrence of depressive symptoms in general population [2]. The urgency of implementing mental health services to address new barriers to care persuaded clinicians to use telemedicine to follow patients and stay in touch with them, and to explore digital therapeutics (DTx) as potential tools for clinical intervention [2]. The combination of antidepressants and psychotherapy is widely recommended for depression by international guidelines [3] but is less frequently applied in real-world practice. Commonly used treatments are pharmacological, but while being effective, some aspects such as adherence to the drug regimen, residual symptoms, resistance, lack of information, and stigma may hinder successful treatment. In case of less severe depression, standalone psychological therapies should be the first-line treatment option [3], but access to trained psychotherapists remains inequitable. DTx are evidence-based therapies driven by software programs to treat or complement treatment of a specific disease. DTx are classified as Medical Devices, and given their therapeutic purpose, they need to be validated through randomized controlled clinical trials, as for drug-based therapies. In the last 10 years, studies of digital interventions have proliferated; these studies demonstrate that digital interventions increase remission rates and lower the severity of depressive symptoms compared with waitlist, treatment as usual, and attention control conditions [4]. Despite the efficacy demonstrated in clinical trials, many of these tools never reach real-life patients; thus, it might be necessary to implement DTx in the public health system to expand access to valid treatment options. In this framework, DTx represent a good opportunity to help people with depression receive optimal psychotherapeutic care [5].

Therapies for obsessive-compulsive disorder: Current state of the art and perspectives for approaching treatment-resistant patients.

Even though obsessive compulsive disorder (OCD) is one of the ten most disabling diseases according to the WHO, only 30-40% of patients suffering from OCD seek specialized treatment. The currently available psychotherapeutic and pharmacological approaches, when properly applied, prove ineffective in about 10% of cases. The use of neuromodulation techniques, especially Deep Brain Stimulation, is highly promising for these clinical pictures and knowledge in this domain is constantly evolving. The aim of this paper is to provide a summary of the current knowledge about OCD treatment, while also discussing the more recent proposals for defining resistance.

[Classification of obsessivecompulsive disorder: evolution in the DSM-V]. / Évolution de la classification du trouble obsessionnel-compulsif dans le DSM-5.

Classification of obsessive-compulsive disorder : evolution in the DSM V. Obsessive-compulsive disorder (OCD) criteria were first described in the third edition of Diagnostic and statistical manual of mental disorders (DSM), in the 1980's. OCD was then classified as an anxious disorder. Today, a new group in DSM-V included OCD and other closed disorders, called "OCD and related disorders". In this new edition, hoarding, before considered as a symptom of OCD, was isolated in a new disorder called hording disorder. This new family also includes body dysmorphic disorder, trichotillomania and skin picking disorder. Criteria of OCD itself are preserved. In DSM-V it was also added the possibility to specify the degree of insight of the patient, and if tics are or were associated with OCD.

Évolution de la classification du trouble obsessionnel-compulsif dans le DSM-5. Les critères diagnostiques du trouble obsessionnel compulsif (TOC) sont apparus dans la 3e édition du Manuel diagnostique et statistique des troubles mentaux (DSM) dans les années 1980. Le TOC était classé dans la catégorie des troubles anxieux. Aujourd'hui, le DSM-5 propose d'isoler le TOC au sein d'une nouvelle famille, celle des TOC et troubles apparentés. Le comportement d'accumulation (amassage), autrefois considéré comme un symptôme du TOC, devient un trouble à part entière, nommé « thésaurisation pathologique ¼. Cette famille comprend également l'obsession de la dysmorphie corporelle, la trichotillomanie et la dermatillomanie. Les grandes lignes des critères diagnostiques du TOC sont conservées. Le DSM-5 ajoute la distinction de différents degrés de prise de conscience (ou insight) du trouble, ainsi que la présence de tics comorbides au TOC.

[Clinical characteristics of obsessivecompulsive disorder]. / Aspects cliniques du trouble obsessionnel-compulsif.

Clinical characteristics of obsessive-compulsive disorder. Obsessive-compulsive disorders (OCD) are composed by repetitive behaviors and intrusive thought, associated with doubt and avoidance. Washers and checkers are the most common dimension of OCD, but it can also be characterized by taboo thoughts or other personalized symptoms. OCD severity could be measured by the Y-BOCS and the balance between obsession and compulsion severity has led to separate 3 kinds of OCD: mostly compulsive, obsessive or mixed. Avoidance should also be included in the measure of OCD severity. How the relatives are involved in OCD symptoms are also an important factor to consider when evaluating the severity and evolution of OCD.

Apects cliniques du trouble obsessionnel-compulsif. Les troubles obsessionnels-compulsifs (TOC) regroupent des idées et comportements répétés, associés à de l'anxiété, du doute et des évitements. Même si les laveurs et les vérificateurs en sont les thématiques les plus répandues, il en existe bien d'autres, dont certaines sont taboues ou personnalisées. La sévérité des TOC peut être évaluée à l'aide la check-list de la Y-BOCS et aussi distinguer des formes majoritairement obsessionnelles, compulsives ou mixtes. Les évitements doivent être aussi pris en compte dans la sévérité de la maladie. L'implication des proches peut également jouer un rôle important dans la sévérité et le maintien du TOC.

Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder: Towards an Individualized Approach.

Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder featuring repetitive intrusive thoughts and behaviors associated with a significant handicap. Of patients, 20% are refractory to medication and cognitive behavioral therapy. Refractory OCD is associated with suicidal behavior and significant degradation of social and professional functioning, with high health costs. Deep brain stimulation (DBS) has been proposed as a reversible and controllable method to treat refractory patients, with meta-analyses showing 60% response rate following DBS, whatever the target: anterior limb of the internal capsule (ALIC), ventral capsule/ventral striatum (VC/VS), nucleus accumbens (NAcc), anteromedial subthalamic nucleus (amSTN), or inferior thalamic peduncle (ITP). But how do we choose the "best" target? Functional neuroimaging studies have shown that ALIC-DBS requires the modulation of the fiber tract within the ventral ALIC via the ventral striatum, bordering the bed nucleus of the stria terminalis and connecting the medial prefrontal cortex with the thalamus to be successful. VC/VS effective sites of stimulation were found within the VC and primarily connected to the medial orbitofrontal cortex (OFC) dorsomedial thalamus, amygdala, and the habenula. NAcc-DBS has been found to reduce OCD symptoms by decreasing excessive fronto-striatal connectivity between NAcc and the lateral and medial prefrontal cortex. The amSTN effective stimulation sites are located at the inferior medial border of the STN, primarily connected to lateral OFC, dorsal anterior cingulate, and dorsolateral prefrontal cortex. Finally, ITP-DBS recruits a bidirectional fiber pathway between the OFC and the thalamus. Thus, these functional connectivity studies show that the various DBS targets lie within the same diseased neural network. They share similar efficacy profiles on OCD symptoms as estimated on the Y-BOCS, the amSTN being the target supported by the strongest evidence in the literature. VC/VS-DBS, amSTN-DBS, and ALIC-DBS were also found to improve mood, behavioral adaptability and potentially both, respectively. Because OCD is such a heterogeneous disease with many different symptom dimensions, the ultimate aim should be to find the most appropriate DBS target for a given refractory patient. This quest will benefit from further investigation and understanding of the individual functional connectivity of OCD patients.

Recent advances in deep brain stimulation in psychiatric disorders.

Deep brain stimulation (DBS) has been offered to patients suffering of severe and resistant neuropsychiatric disorders like Obsessive Compulsive Disorder (OCD), Gilles de la Tourette Syndrome (TS) and Major Depression (MDD). Modulation of several targets within the cortico-striato-thalamo-cortical circuits can lead to a decrease of symptom severity in those patients. This review focuses on the recent clinical outcomes in DBS in psychiatric disorders. Studies on OCD and TS are now focusing on the long-term effects of DBS, with encouraging results regarding not only the decrease of symptoms, but also quality of life. They also highlighted efficient adjuvant techniques, like cognitive and behavioural therapy and support programs, to enhance an often-partial response to DBS. The application of DBS for MDD is more recent and, despite encouraging initial open-label studies, two large randomised studies have failed to demonstrate an efficacy of DBS in MDD according to evidence-based medicine criteria. Last years, DBS was also tested in other resistant psychiatric disorders, as anorexia nervosa and addiction, with encouraging preliminary results. However, today, no target - whatever the disease - can meet the criteria for clinical efficacy as recently defined by an international committee for neurosurgery for psychiatric disorders. Consequently, DBS in psychiatric disorders still needs to proceed within the frame of clinical trials.

Altered anatomical connections of associative and limbic cortico-basal-ganglia circuits in obsessive-compulsive disorder.

BACKGROUND: Current neurocognitive models suppose dysfunctions of associative and limbic cortico-basal ganglia circuits to be at the core of obsessive-compulsive disorder (OCD). As little is known about the state of underlying anatomical connections, we investigated whether these connections were reduced and/or not properly organised in OCD patients compared to control. METHODS: Diffusion magnetic resonance images were obtained in 37 OCD patients with predominant checking symptoms and 37 matched healthy controls. We developed indices to characterise the quantity (spatial extent and density) and the organisation (topography and segregation) of 24 anatomical connections between associative and limbic cortical (anterior cingulate, dorsolateral prefrontal, orbitofrontal cortices and the frontal pole), and subcortical (caudate nucleus, putamen and thalamus) areas in each hemisphere. RESULTS: Associative and limbic cortico-basal-ganglia connections were reduced in OCD patients compared to controls: 19/24 connections had a reduced subcortical spatial extent, 9/24 had a reduced density. Moreover, while the general topography was conserved, the different cortical projection fields in the striatum and thalamus were hyper-segregated in OCD patients compared to controls. CONCLUSION: These quantitative and qualitative differences of anatomical connections go beyond the current model of a reduced cortical control of automatic behaviour stored in the basal ganglia. The hyper-segregation in OCD could also impair the integration of cortical information in the thalamus and striatum and distort the subsequent behavioural selection process. This provides new working hypotheses for functional and behavioural studies on OCD.

Neuronal activity correlated with checking behaviour in the subthalamic nucleus of patients with obsessive-compulsive disorder.

Doubt, and its behavioural correlate, checking, is a normal phenomenon of human cognition that is dramatically exacerbated in obsessive-compulsive disorder. We recently showed that deep brain stimulation in the associative-limbic area of the subthalamic nucleus, a central core of the basal ganglia, improved obsessive-compulsive disorder. To understand the physiological bases of symptoms in such patients, we recorded the activity of individual neurons in the therapeutic target during surgery while subjects performed a cognitive task that gave them the possibility of unrestricted repetitive checking after they had made a choice. We postulated that the activity of neurons in this region could be influenced by doubt and checking behaviour. Among the 63/87 task-related neurons recorded in 10 patients, 60% responded to various combinations of instructions, delay, movement or feedback, thus highlighting their role in the integration of different types of information. In addition, task-related activity directed towards decision-making increased during trials with checking in comparison with those without checking. These results suggest that the associative-limbic subthalamic nucleus plays a role in doubt-related repetitive thoughts. Overall, our results not only provide new insight into the role of the subthalamic nucleus in human cognition but also support the fact that subthalamic nucleus modulation by deep brain stimulation reduced compulsive behaviour in patients with obsessive-compulsive disorder.

Similar improvement of reward and punishment learning by serotonin reuptake inhibitors in obsessive-compulsive disorder.

BACKGROUND: The role of dopamine in reinforcement learning has been extensively studied, but the role of other major neuromodulators, particularly serotonin, remains poorly understood. An influential theory has suggested that dopamine and serotonin represent opponent systems respectively driving reward and punishment learning. METHODS: To test this theory, we compared two groups of patients with obsessive-compulsive disorder, one unmedicated (n = 12) and one treated with serotonin reuptake inhibitors (SRI; n = 13). To avoid confounding basic reinforcement learning with strategic conscious reasoning, we used a subliminal conditioning task that involves subjects learning to associate masked cues with gambling outcomes to maximize their payoff. The same task was used in a previous study to demonstrate opposite effects of dopaminergic medication on reward and punishment learning. RESULTS: Unmedicated obsessive-compulsive disorder patients exhibited an instrumental learning deficit that was fully alleviated under SRI treatment. Contrary to dopaminergic medication, SRIs similarly modulated reward and punishment learning. CONCLUSIONS: Thus, departing from the opponency model, our results support a beneficial role of serotonin in instrumental learning that is independent of outcome valence.